Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Shares of pharmaceutical company 4D Pharma (LON: DDDD) are climbing on Monday after the company announced a collaboration with Parkinson’s UK, a non-profit organisation focused on Parkinson’s disease.
A new Patient Advisory Board will be established, comprised of people living with Parkinson’s.
Supported by Parkinson's UK, the Board will provide a patient-centric perspective to 4D pharma as it continues to advance novel Live Biotherapeutics to treat neurodegenerative conditions such as Parkinson's. The Board will also raise awareness of the issues people with Parkinson's face with current treatment options.
4D Pharma works in the development of live biotherapeutics, an emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that applies to the prevention, treatment or cure of a disease.
They currently have three preclinical trials ongoing that are focused on neurodegenerative and neurodevelopmental diseases.
“The contributions of our Patient Advisory Board, with the support of Parkinson's UK, will be vital to 4D pharma's efforts to not only develop novel therapeutics for this devastating condition, but also promote a dialogue and partnership with the Parkinson's patient community,” said Alex Stevenson, Chief Scientific Officer, 4D pharma.
4D Pharma’s share price is up 2.15% so far on Monday morning, priced at 119.4p.
4D Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are 4D Pharma shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .